[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
Views 77
Citations 0
Editor's Correspondence
Sep 24, 2012

Raise the Bar Even Higher for Primary Prevention Interventions—Reply

Author Affiliations

Author Affiliations: Department of Medicine, Northwestern University, Chicago, Illinois (Dr Prasad); and Department of Medicine, Yale University, New Haven, Connecticut (Dr Vandross).

Arch Intern Med. 2012;172(17):1352-1353. doi:10.1001/archinternmed.2012.3963

In reply

In our article on cardiovascular primary prevention,1 we argue that the bar must be raised. A net clinical benefit should be demonstrated before novel agents are introduced into practice. We use overall mortality as a benchmark for this benefit. Wright and colleagues extend our claim, noting that morbidity must be taken into account. In principle, we agree with their comments. A drug that improves survival, but significantly worsens quality of life, would not constitute a net clinical benefit.

×